• +1-646-491-9876
    • +91-20-67278686

    Search

    Macular Edema-Pipeline Review H1 2017

    Macular Edema-Pipeline Review H1 2017

    • Report Code ID: RW0001834401
    • Category Pharmaceuticals
    • No. of Pages 43
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Macular Edema - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H1 2017, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

    Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 6, 2 and 1 respectively.

    Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology) .
    - The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Macular Edema - Overview
    Macular Edema - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Macular Edema - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Macular Edema - Companies Involved in Therapeutics Development
    ActiveSite Pharmaceuticals Inc
    Coherus BioSciences Inc
    Lupin Ltd
    Mabion SA
    Pfizer Inc
    Promedior Inc
    Taiwan Liposome Company Ltd
    Valeant Pharmaceuticals International Inc
    Xbrane Biopharma AB
    Macular Edema - Drug Profiles
    ACX-107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aflibercept biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASPPDC-020 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLO-021 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    celecoxib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dexamethasone sodium phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HO-10 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRM-167 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ranibizumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ranibizumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ranibizumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Macular Edema - Dormant Projects
    Macular Edema - Discontinued Products
    Macular Edema - Product Development Milestones
    Featured News & Press Releases
    Oct 01, 2015: Patent Granted by SIPO for TLCs Ophthalmic Drug Delivery System
    Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC's Ophthalmology Drug Phase I/II trial
    Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug
    Sep 24, 2013: Patent Approval granted by USPTO for TLC's BioSeizer Platform
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Macular Edema, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
    Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2017
    Macular Edema - Pipeline by Lupin Ltd, H1 2017
    Macular Edema - Pipeline by Mabion SA, H1 2017
    Macular Edema - Pipeline by Pfizer Inc, H1 2017
    Macular Edema - Pipeline by Promedior Inc, H1 2017
    Macular Edema - Pipeline by Taiwan Liposome Company Ltd, H1 2017
    Macular Edema - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
    Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2017
    Macular Edema - Dormant Projects, H1 2017
    Macular Edema - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Macular Edema, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    ActiveSite Pharmaceuticals Inc
    Coherus BioSciences Inc
    Lupin Ltd
    Mabion SA
    Pfizer Inc
    Promedior Inc
    Taiwan Liposome Company Ltd
    Valeant Pharmaceuticals International Inc
    Xbrane Biopharma AB

    Request for Sample

    Report Url http://www.reportsweb.com//macular-edema-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//macular-edema-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//macular-edema-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments